Protein tyrosine phosphatase-1B in diabetes

Biochemical Pharmacology

Volumn 60, Issue 7, 2000, Pages 877-883

  Kennedy, Brian P ^a   Ramachandran, Chidambaram ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Diabetes; Insulin signaling; Obesity; PTP 1B

Indexed keywords

INSULIN; INSULIN RECEPTOR; PHOSPHONIC ACID DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; VANADIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBUNIT; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0034308201     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00305-1     Document Type: Article

References (85)

1. White M.F., Kahn C.R. The insulin signaling system. J Biol Chem. 269:1994;1-4.
2. Gustafson T.A., Moodie S.A., Lavan B.E. The insulin receptor and metabolic signaling. Rev Physiol Biochem Pharmacol. 137:1999;71-190.
3. Taha C., Klip A. The insulin signaling pathway. J Membr Biol. 169:1999;1-12.
4. Tonks N.K., Diltz C.D., Fischer E.H. Purification of the major protein-tyrosine- phosphatases of human placenta. J Biol Chem. 263:1988;6722-6730.
5. McGuire M.C., Fields R.M., Nyomba B.L., Raz I., Bogardus C., Tonks N.K., Sommercorn J. Abnormal regulation of protein tyrosine phosphatase activities in skeletal muscle of insulin-resistant humans. Diabetes. 40:1991;939-942.
6. Goldstein B.J., Ahmad F., Ding W., Li P.-M., Zhang W.-R. Regulation of the insulin signalling pathway by cellular protein-tyrosine phosphatases. Mol Cell Biochem. 182:1998;91-99.
7. Goldfine A.B., Simonson D.C., Folli F., Patti M.E., Kahn C.R. In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus. Mol Cell Biochem. 53:1995;217-231.
8. Cohen N., Halberstam M., Shlimovich P., Chang C.J., Shamoon H., Rossetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 95:1995;2501-2509.
9. Elchebly M., Payette P., Michaliszyn E., Cromlish W., Collins S., Loy A.L., Normandin D., Cheng A., Himms-Hagen J., Chan C.C., Ramachandran C., Gresser M.J., Tremblay M.L., Kennedy B.P. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 283:1999;1544-1548.
10. Evans J.L., Jallal B. Protein tyrosine phosphatases Their role in insulin action and potential as drug targets . Expert Opin Invest Drugs. 8:1999;139-160.
11. Byon J.C., Kusari A.B., Kusari J. Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction. Mol Cell Biochem. 182:1998;101-108.
12. Mustelin T., Brockdorff J., Gjörloff-Wingren A., Tailor P., Han S., Wang X., Saxena M. Lymphocyte activation The coming of the protein tyrosine phosphatases . Front Biosci. 3:1998;1060-1096.
13. Zhang Z.Y. Protein-tyrosine phosphatases Biological function, structural characteristics, and mechanism of catalysis . Crit Rev Biochem Mol Biol. 33:1998;1-52.
14. Neel B.G., Tonks N.K. Protein tyrosine phosphatases in signal transduction. Curr Opin Cell Biol. 9:1997;193-204.
15. Kishihara K., Penninger J., Wallace V.A., Kündig T.M., Kawai K., Wakeham A., Timms E., Pfeffer K., Ohashi P.S., Thomas M.L., Furlonger C., Paige C.J., Mak T.W. Normal B lymphocyte development but impaired T cell maturation in CD45-exon 6 protein tyrosine phosphatase-deficient mice. Cell. 74:1993;143-156.
16. Saxton T.M., Henkemeyer M., Gasca S., Shen R., Rossi D.J., Shalaby F., Feng G.-S., Pawson T. Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. EMBO J. 16:1997;2352-2364.
17. Côté J.-F., Charest A., Wagner J., Tremblay M.L. Combination of gene targeting and substrate trapping to identify substrates of protein tyrosine phosphatases using PTP-PEST as a model. Biochemistry. 37:1998;13128-13137.
18. Elchebly M., Wagner J., Kennedy T.E., Lanctot C., Michaliszyn E., Itié A., Drouin J., Tremblay M.L. Neuroendocrine dysplasia in mice lacking protein tyrosine phosphatase σ Nat Genet. 21:1999;330-333.
19. You-Ten K.E., Muise E.S., Itié A., Michaliszyn E., Wagner J., Jothy S., Lapp W.S., Tremblay M.L. Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J Exp Med. 186:1997;683-693.
20. D'Ambrosio D., Hippen K.L., Minskoff S.A., Mellman I., Pani G., Siminovitch K.A., Cambier J.C. Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by FcγRIIB1. Science. 268:1995;293-297.
21. Schaapveld R.Q.J., Schepens J.T.G., Robinson G.W., Attema J., Oerlemans F.T.J.J., Fransen J.A.M., Streuli M., Wieringa B., Hennighausen L., Hendriks W.J.A.J. Impaired mammary gland development and function in mice lacking LAR receptor-like tyrosine phosphatase activity. Dev Biol. 188:1997;134-146.
22. Ren J.M., Li P.M., Zhang W.R., Sweet L.J., Cline G., Shulman G.I., Livingston J.N., Goldstein B.J. Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose homeostasis. Diabetes. 47:1998;493-497.
23. Norris K., Norris F., Kono D.H., Vestergaard H., Pedersen O., Theofilopoulos A.N., Moller N.P. Expression of protein-tyrosine phosphatases in the major insulin target tissues. FEBS Lett. 415:1997;243-248.
24. Flint A.J., Tiganis T., Barford D., Tonks N.K. Development of, "substrate-trapping" mutants to identify physiological substrates of protein tyrosine phosphatases. Proc Natl Acad Sci USA. 94:1997;1680-1685.
25. Liu F., Chernoff J. Protein tyrosine phosphatase 1B interacts with and is tyrosine phosphorylated by the epidermal growth factor receptor. Biochem J. 327:1997;139-145.
26. Seely B.L., Staubs P.A., Reichart D.R., Berhanu P., Milarski K.L., Saltiel A.R., Kusari J., Olefsky J.M. Protein tyrosine phosphatase 1B interacts with the activated insulin receptor. Diabetes. 45:1996;1379-1385.
27. Bandyopadhyay D., Kusari A., Kenner K.A., Liu F., Chernoff J., Gustafson T.A., Kusari J. Protein-tyrosine phosphatase 1B complexes with the insulin receptor in vivo and is tyrosine-phosphorylated in the presence of insulin. J Biol Chem. 272:1997;1639-1645.
28. Ramachandran C., Aebersold R., Tonks N.K., Pot D.A. Sequential dephosphorylation of a multiply phosphorylated insulin receptor peptide by protein tyrosine phosphatases. Biochemistry. 31:1992;4232-4238.
29. Desmarais S., Friesen R.W., Zamboni R., Ramachandran C. [Difluro(phosphono)methyl]phenylalanine-containing peptide inhibitors of protein tyrosine phosphatases. Biochem J. 337:1999;219-223.
30. Frangioni J.V., Beahm P.H., Shifrin V., Jost C.A., Neel B.G. The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence. Cell. 68:1992;545-560.
31. Drake P.G., Posner B.I. Insulin receptor-associated protein tyrosine phosphatase(s) Role in insulin action . Mol Cell Biochem. 182:1998;79-89.
32. Kahn B.B. Type 2 diabetes When insulin secretion fails to compensate for insulin resistance . Cell. 92:1998;593-596.
33. Taylor S.I. Deconstructing type 2 diabetes. Cell. 97:1999;9-12.
34. Lebovitz H.E. Type 2 diabetes An overview . Clin Chem. 45:1999;1339-1345.
35. Bailey C.J. Insulin resistance and antidiabetic drugs. Biochem Pharmacol. 58:1999;1511-1520.
36. Brady M.J., Saltiel A.R. Closing in on the cause of insulin resistance and type 2 diabetes. J Clin Invest. 104:1999;675-676.
37. iα2. Nature. 379:1996;840-844.
38. Meyerovitch J., Rothenberg P., Shechter Y., Bonner-Weir S., Kahn C.R. Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. J Clin Invest. 87:1991;1286-1294.
39. Sredy J., Sawicki D.R., Flam B.R., Sullivan D. Insulin resistance is associated with abnormal dephosphorylation of a synthetic phosphopeptide corresponding to the major autophosphorylation sites of the insulin receptor. Metabolism. 44:1995;1074-1081.
40. Ahmad F., Goldstein B.J. Increased abundance of specific skeletal muscle protein-tyrosine phosphatases in a genetic model of insulin-resistant obesity and diabetes mellitus. Metabolism. 44:1995;1175-1184.
41. Worm D., Handberg A., Hoppe E., Vinten J., Beck-Nielsen H. Decreased skeletal muscle phosphotyrosine phosphatase (PTPase) activity towards insulin receptors in insulin-resistant Zucker rats measured by delayed Europium fluorescence. Diabetologia. 39:1996;142-148.
42. Begum N., Sussman K.E., Draznin B. Differential effects of diabetes on adipocyte and liver phosphotyrosine and phosphoserine phosphatase activities. Diabetes. 40:1991;1620-1629.
43. Hauguel-de Mouzon S., Peraldi P., Alengrin F., Van Obberghen E. Alteration of phosphotyrosine phosphatase activity in tissues from diabetic and pregnant rats. Endocrinology. 132:1993;67-74.
44. Ahmad F., Goldstein B.J. Alterations in specific protein-tyrosine phosphatases accompany insulin resistance of streptozotocin diabetes. Am J Physiol. 268:1995;E932-E940.
45. Boylan J.M., Brautigan D.L., Madden J., Raven T., Ellis L., Gruppuso P.A. Differential regulation of multiple hepatic protein tyrosine phosphatases in alloxan diabetic rats. J Clin Invest. 90:1992;174-179.
46. Olichon-Berthe C. Hauguel-De Mouzon S, Péraldi P, Van Obberghen E and Le Marchand-Brustel Y, Insulin receptor dephosphorylation by phosphotyrosine phosphatases obtained from insulin-resistant obese mice. Diabetologia. 37:1994;56-60.
47. Ahmad F., Azevedo J.L., Cortright R., Dohm G.L., Goldstein B.J. Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J Clin Invest. 100:1997;449-458.
48. Kusari J., Kenner K.A., Suh K.I., Hill D.E., Henry R.R. Skeletal muscle protein tyrosine phosphatase activity and tyrosine phosphatase 1B protein content are associated with insulin action and resistance. J Clin Invest. 93:1994;1156-1162.
49. Worm D., Vinten J., Staehr P., Henriksen J.E., Handberg A., Beck-Nielsen H. Altered basal and insulin-stimulated phosphotyrosine phosphatase (PTPase) activity in skeletal muscle from NIDDM patients compared with control subjects. Diabetologia. 39:1996;1208-1214.
50. Ahmad F., Considine R.V., Goldstein B.J. Increased abundance of the receptor-type protein-tyrosine phosphatase LAR accounts for the elevated insulin receptor dephosphorylating activity in adipose tissue of obese human subjects. J Clin Invest. 95:1995;2806-2812.
51. Cheung A., Kusari J., Jansen D., Bandyopadhyay D., Kusari A., Bryer-Ash M. Marked impairment of protein tyrosine phosphatase 1B activity in adipose tissue of obese subjects with and without type 2 diabetes mellitus. J Lab Clin Med. 134:1999;115-123.
52. Caro J.F., Sinha M.K., Raju S.M., Ittoop O., Pories W.J., Flickinger E.G., Meelheim D., Dohm G.L. Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes. J Clin Invest. 79:1987;1330-1337.
53. Hotamisligil G.S., Budavari A., Murray D., Spiegelman B.M. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-α J Clin Invest. 94:1994;1543-1549.
54. Lembertas A.V., Perusse L., Chagnon Y.C., Fisler J.S., Warden C.H., Purcell-Huynh D.A., Dionne F.T., Gagnon J., Nadeau A., Lusis A.J., Bouchard C. Identification of an obesity quantitative trait locus on mouse chromosome 2 and evidence of linkage to body fat and insulin on the human homologous region 20q. J Clin Invest. 100:1997;1240-1247.
55. Lee J.H., Reed D.R., Li W.D., Xu W., Joo E.J., Kilker R.L., Nanthakumar E., North M., Sakul H., Bell C., Price R.A. Genome scan for human obesity and linkage to markers in 20q13. Am J Hum Genet. 64:1999;196-209.
56. Brown-Shimer S., Johnson K.A., Lawrence J.B., Johnson C., Bruskin A., Green N.R., Hill D.E. Molecular cloning and chromosome mapping of the human gene encoding protein phosphotyrosyl phosphatase 1B. Proc Natl Acad Sci USA. 87:1990;5148-5152.
57. Porte D. Jr, Seeley R.J., Woods S.C., Baskin D.G., Figlewicz D.P., Schwartz M.W. Obesity, diabetes and the central nervous system. Diabetologia. 41:1998;863-881.
58. Sipols A.J., Baskin D.G., Schwartz M.W. Effect of intracerebroventricular insulin infusion on diabetic hyperphagia and hypothalamic neuropeptide gene expression. Diabetes. 44:1995;147-151.
59. Ikeda H., West D.B., Pustek J.J., Figlewicz D.P., Greenwood M.R., Porte D. Jr, Woods S.C. Intraventricular insulin reduces food intake and body weight of lean but not obese Zucker rats. Appetite. 7:1986;381-386.
60. Meyerovitch J., Shechter Y., Amir S. Vanadate stimulates in vivo glucose uptake in brain and arrests food intake and body weight gain in rats. Physiol Behav. 45:1989;1113-1116.
61. Hooft van Huijsduijnen R. Protein tyrosine phosphatases Counting the trees in the forest . Gene. 225:1998;1-8.
62. Huyer G., Liu S., Kelly J., Moffat J., Payette P., Kennedy B., Tsaprailis G., Gresser M.J., Ramachandran C. Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate. J Biol Chem. 272:1997;843-851.
63. Denu J.M., Lohse D.L., Vijayalakshmi J., Saper M.A., Dixon J.E. Visualization of intermediate and transition-state structures in protein-tyrosine phosphatase catalysis. Proc Natl Acad Sci USA. 93:1996;2493-2498.
64. Cuncic C., Detich N., Ethier D., Tracey A.S., Gresser M.J., Ramachandran C. Vanadate inhibition of protein tyrosine phosphatases in Jurkat cells Modulation by redox state . J Biol Inorg Chem. 4:1999;354-359.
65. Poucheret P., Verma S., Grynpas M.D., McNeil J.H. Vanadium and diabetes. Mol Cell Biochem. 188:1998;73-80.
66. Crans D.C. Peroxo, hydroxylamido and acac derived vanadium complexes Chemistry, biochemistry and insulin-mimetic actions of selected vanadium compounds . ACS Symp Ser. 711:1998;82-103.
67. Posner B.I., Faure R., Burgess J.W., Bevan A.P., Lachance D., Zhang-Sun G., Fantus I.G., Ng J.B., Hall D.A., Lum B.S. Peroxovanadium compounds A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics . J Biol Chem. 269:1994;4596-4604.
68. Hiriyanna K.T., Baedke D., Baek K.H., Forney B.A., Kordiyak G., Ingebritsen T.S. Thiophosphorylated substrate analogs are potent active site-directed inhibitors of protein-tyrosine phosphatases. Anal Biochem. 223:1994;51-58.
69. Liotta A.S., Kole H.K., Fales H.M., Roth J., Bernier M.A. Synthetic tris-sulfotyrosyl dodecapeptide analogue of the insulin receptor 1146-kinase domain inhibits tyrosine dephosphorylation of the insulin receptor in situ. J Biol Chem. 269:1994;22996-23001.
70. Desmarais S., Jia Z., Ramachandran C. Inhibition of protein tyrosine phosphatases PTP1B and CD45 by sulfotyrosyl peptides. Arch Biochem Biophys. 354:1998;225-231.
71. 2Pmp. Biochem Biophys Res Commun. 204:1994;129-134.
72. Chen L., Wu L., Otaka A., Smyth M.S., Roller P.P., Burke T.R. Jr, den Hertog J., Zhang Z.Y. Why is phosphonodifluoromethyl phenylalanine a more potent inhibitory moiety than phosphonomethyl phenylalanine toward protein-tyrosine phosphatases? Biochem Biophys Res Commun. 216:1995;976-984.
73. Kole H.K., Akamatsu M., Ye B., Yan X., Barford D., Roller P.P., Burke T.R. Jr. Protein-tyrosine phosphatase inhibition by a peptide containing the phosphotyrosyl mimetic L-O-malonyltyrosine. Biochem Biophys Res Commun. 209:1995;817-822.
74. Burke T.R. Jr, Ye B., Akamatsu M., Ford H. Jr, Yan X., Kole H.K., Wolf G., Shoelson S.E., Roller P.P. 4′-O-[2-(2-Fluoromalonyl)]-L-tyrosine A phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides . J Med Chem. 39:1996;1021-1027.
75. Zhang Z.-Y., Maclean D., McNamara D.J., Sawyer T.K., Dixon J.E. Protein tyrosine phosphatase substrate specificity Size and phosphotyrosine positioning requirements in peptide substrates . Biochemistry. 33:1994;2285-2290.
76. Huyer G., Kelly J., Moffat J., Zamboni R., Jia Z., Gresser M.J., Ramachandran C. Affinity selection from peptide libraries to determine substrate specificity of protein tyrosine phosphatases. Anal Biochem. 258:1998;19-30.
77. Montserat J., Chen L., Lawrence D.S., Zhang Z.Y. Potent low molecular weight substrates for protein-tyrosine phosphatase. J Biol Chem. 271:1996;7868-7872.
78. Kole H.K., Smyth M.S., Russ P.L., Burke T.R. Jr. Phosphonate inhibitors of protein- tyrosine and serine/threonine phosphatases. Biochem J. 311:1995;1025-1031.
79. Burke T.R. Jr, Ye B., Yan X., Wang S., Jia Z., Chen L., Zhang Z.Y., Barford D. Small molecule interactions with protein-tyrosine phosphatase PTP1B and their use in inhibitor design. Biochemistry. 35:1996;15989-15996.
80. Taylor S.D., Kotoris C.C., Dinaut A.N., Wang Q., Ramachandran C., Huang Z. Potent non-peptidyl inhibitors of protein tyrosine phosphatase 1B. Bioorg Med Chem. 6:1998;1457-1468.
81. Wang Q., Huang Z., Ramachandran C., Dinaut A.N., Taylor S.D. Naphthalenebis[α,α-difluoromethylenephosphonates] as potent inhibitors of protein tyrosine phosphatases. Bioorg Med Chem Lett. 8:1998;345-350.
82. Kotoris C.C., Chen M.J., Taylor S.D. Novel phosphate mimetics for the design of non-peptidyl inhibitors of protein tyrosine phosphatases. Bioorg Med Chem Lett. 8:1998;3275-3280.
83. Taing M., Keng Y.F., Shen K., Wu L., Lawrence D.S., Zhang Z.Y. Potent and highly selective inhibitors of the protein tyrosine phosphatase 1B. Biochemistry. 38:1999;3793-3803.
84. Puius Y.A., Zhao Y., Sullivan M., Lawrence D.S., Almo S.C., Zhang Z.Y. Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B A paradigm for inhibitor design . Proc Natl Acad Sci USA. 94:1997;13420-13425.
85. Wrobel J., Sredy J., Moxham C., Dietrich A., Li Z., Sawicki D.R., Seestaller L., Wu L., Katz A., Sullivan D., Tio C., Zhang Z.Y. PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes. J Med Chem. 42:1999;3199-3202.